Property Summary

NCBI Gene PubMed Count 499
PubMed Score 1988.79
PubTator Score 2077.29

Knowledge Summary


No data available


  Disease Sources (5)

Disease Target Count P-value
non-small cell lung cancer 2798 7.1437340277658E-15
pilocytic astrocytoma 3086 2.15729888315407E-8
ulcerative colitis 2087 4.1369045413845E-7
lung adenocarcinoma 2714 4.43369433460018E-7
cystic fibrosis 1670 9.20729458799895E-7
tuberculosis 1563 1.3798943325198E-5
nasopharyngeal carcinoma 1056 1.58935772920383E-5
atypical teratoid / rhabdoid tumor 4369 1.80046533572288E-5
ovarian cancer 8492 3.53432502089746E-5
glioblastoma 5572 4.46749506477177E-5
medulloblastoma, large-cell 6234 6.41259163439283E-5
psoriasis 6685 1.48366165427935E-4
interstitial cystitis 2299 2.23401542187495E-4
Atopic dermatitis 944 2.3207038579658E-4
adult high grade glioma 2148 4.06437139239762E-4
Multiple Sclerosis 498 6.50380468521575E-4
primary pancreatic ductal adenocarcinoma 1271 0.00105811683453517
osteosarcoma 7933 0.00251011568753006
non diabetic and post-ischemic heart failure 200 0.00257861764723759
ependymoma 2514 0.00274313698583411
pancreatic cancer 2300 0.00311621443614487
intraductal papillary-mucinous adenoma (IPMA) 2956 0.00726328950770933
colon cancer 1475 0.00803270927732057
primitive neuroectodermal tumor 3031 0.0192090690566837
Breast cancer 3099 0.0248609387717636
gastric carcinoma 832 0.0272531072481332
interstitial lung disease 292 0.0428307424639906
invasive ductal carcinoma 2950 0.0471595753273047
Disease Target Count Z-score Confidence
Crohn's disease 304 0.0 2.0



Accession P00749 B4DPZ2 Q15844 Q16618 Q53XS3 Q5SWW9 Q969W6 U-plasminogen activator
Symbols ATF


PANTHER Protein Class (3)


1C5W   1C5X   1C5Y   1C5Z   1EJN   1F5K   1F5L   1F92   1FV9   1GI7   1GI8   1GI9   1GJ7   1GJ8   1GJ9   1GJA   1GJB   1GJC   1GJD   1KDU   1LMW   1O3P   1O5A   1O5B   1O5C   1OWD   1OWE   1OWH   1OWI   1OWJ   1OWK   1SC8   1SQA   1SQO   1SQT   1U6Q   1URK   1VJ9   1VJA   1W0Z   1W10   1W11   1W12   1W13   1W14   2FD6   2I9A   2I9B   2NWN   2O8T   2O8U   2O8W   2R2W   2VIN   2VIO   2VIP   2VIQ   2VIV   2VIW   2VNT   3BT1   3BT2   3IG6   3KGP   3KHV   3KID   3M61   3MHW   3MWI   3OX7   3OY5   3OY6   3PB1   3QN7   3U73   4DVA   4DW2   4FU7   4FU8   4FU9   4FUB   4FUC   4FUD   4FUE   4FUF   4FUG   4FUH   4FUI   4FUJ   4GLY   4H42   4JK5   4JK6   4JNI   4JNL   4K24   4MNV   4MNW   4MNX   4MNY   4OS1   4OS2   4OS4   4OS5   4OS6   4OS7   4X0W   4X1N   4X1P   4X1Q   4X1R   4X1S   4XSK   4ZHL   4ZHM   4ZKN   4ZKO   4ZKR   4ZKS   5HGG  

  Ortholog (13)

 IMPC Term (1)

MLP Assay (1)

AID Type Active / Inconclusive / Inactive Description
720519 confirmatory 16 / 44 / 827 qHTS for Inhibitors of Cell Surface uPA Generation: Confirmatory Assay for Cherry-picked Compounds

Gene RIF (438)

26978018 The morphologically normal tissue adjacent to the tumor shows the substantial expression of MMP-2 and MMP-9 and in some cases the enhanced activity of uPA and ACE, which makes an additional contribution to the increased invasive potential of tumor
26846181 Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
26782341 1,25D3 works as a modifier of NF-kappaB/GPX1/uPA expression, inhibiting cisplatin-resistance and cell invasive ability of salivary adenoid cystic carcinoma cells
26707376 Resveratrol inhibited hypoxia-induced HIF-1alpha protein expression. Resveratrol also suppressed hypoxiainduced expression of metastatic-related factors, uPA and MMP2.
26643086 These findings strongly support the use of uPA/PAI-1 together with clinic-pathological parameters as an evidence-based, clinically relevant and inexpensive decision tool in the routine of a breast center.
26504024 High cytoplasmic expression of uPA is associated with cells of rectal cancer and metastases of perienteric lymph nodes.
26317203 Results found high levels of uPA and uPAR exclusively in metastatic osteosarcoma (OS)cells and suggest that malignant conversion of OS cells to uPA/uPAR axis in an autocrine and paracrine fashion.
26166362 it was found that the recombinant fusion protein uPA17-34-KPI(kunitz-type protease inhibitor ) inhibited the invasion and metastasis of ovarian tumors
26050228 data on the stromal macrophages immunoreactivity of uPAR, MMP-2, and MMP-9 in a few small cell lung cancer (SCLC) and lung squamous cell carcinoma (SCC) biopsies was included. uPAR, MMP-2, and MMP-9 were confirmed in stromal cells including macrophages
26033187 u-PA is a dysregulated gene involved in the tumorigenesis, bio-pathological features and outcomes of EEC.

AA Sequence

SHTKEENGLAL                                                               421 - 431

Text Mined References (502)

PMID Year Title
26978018 [Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].
26846181 2016 Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
26782341 2016 1,25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-?B pathway.
26707376 2016 Resveratrol inhibits hypoxia-driven ROS-induced invasive and migratory ability of pancreatic cancer cells via suppression of the Hedgehog signaling pathway.
26643086 2016 Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
26504024 2015 Plasminogen Activation System in Rectal Adenocarcinoma.
26317203 2015 Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.
26166362 2015 Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
26050228 2015 Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
26033187 2015 Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients.